|Bid||47.30 x 800|
|Ask||47.32 x 1000|
|Day's range||47.19 - 47.53|
|52-week range||42.29 - 59.00|
|Beta (5Y monthly)||0.26|
|PE ratio (TTM)||30.98|
|Earnings date||26 Jul 2021 - 30 Jul 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||58.20|
HILDEN, Germany, & GERMANTOWN, Md., Jun 21, 2021--QIAGEN launches dedicated CRISPR products for rapid and simplified analysis of gene-editing experiments
Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
QIAGEN's (QGEN) therascreen KRAS kit to be used with LUMAKRAS is claimed to provide clinicians with a wide range of biomarker testing options, critical to patients with NSCLC.